IMVT Earnings Immunovant, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–31 of 31
| Q1 2027 | 2026-06-30 | -0.75 | 2026-08-06 | 10-Q |
| Q4 2026 (derived) | 2026-03-31 | -0.72 | 2026-05-20 | 10-K |
| FY 2026 | 2026-03-31 | -2.77 | 2026-05-20 | 10-K |
| Q3 2026 | 2025-12-31 | -0.61 | 2026-02-06 | 10-Q |
| Q2 2026 | 2025-09-30 | -0.73 | 2025-11-10 | 10-Q |
| Q1 2026 | 2025-06-30 | -0.71 | 2025-08-11 | 10-Q |
| Q4 2025 (derived) | 2025-03-31 | -0.63 | 2025-05-29 | 10-K |
| FY 2025 | 2025-03-31 | -2.73 | 2025-05-29 | 10-K |
| Q3 2025 | 2024-12-31 | -0.76 | 2025-02-06 | 10-Q |
| Q2 2025 | 2024-09-30 | -0.74 | 2024-11-07 | 10-Q |
| Q1 2025 | 2024-06-30 | -0.60 | 2024-08-06 | 10-Q |
| Q4 2024 (derived) | 2024-03-31 | -0.50 | 2024-05-29 | 10-K |
| FY 2024 | 2024-03-31 | -1.88 | 2024-05-29 | 10-K |
| Q3 2024 | 2023-12-31 | -0.36 | 2024-02-12 | 10-Q |
| Q2 2024 | 2023-09-30 | -0.45 | 2023-11-09 | 10-Q |
| Q1 2024 | 2023-06-30 | -0.57 | 2023-08-10 | 10-Q |
| Q4 2023 (derived) | 2023-03-31 | -0.46 | 2023-05-22 | 10-K |
| FY 2023 | 2023-03-31 | -1.71 | 2023-05-22 | 10-K |
| Q3 2023 | 2022-12-31 | -0.49 | 2023-02-03 | 10-Q |
| Q2 2023 | 2022-09-30 | -0.41 | 2022-11-04 | 10-Q |
| Q1 2023 | 2022-06-30 | -0.35 | 2022-08-05 | 10-Q |
| Q4 2022 (derived) | 2022-03-31 | -0.41 | 2022-06-08 | 10-K |
| FY 2022 | 2022-03-31 | -1.43 | 2022-06-08 | 10-K |
| Q3 2022 | 2021-12-31 | -0.36 | 2022-02-04 | 10-Q |
| Q2 2021 | 2021-09-30 | -0.35 | 2021-11-05 | 10-Q |
| Q1 2021 | 2021-06-30 | -0.31 | 2021-08-09 | 10-Q |
| Q4 2021 (derived) | 2021-03-31 | -0.27 | — | — |
| FY 2021 | 2021-03-31 | -1.22 | — | — |
| Q3 2021 | 2020-12-31 | -0.32 | — | — |
| Q2 2020 | 2020-09-30 | -0.25 | — | — |
| Q1 2020 | 2020-06-30 | -0.38 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.